Table 5.
Summary of Results for Selected Studies Utilizing EUS-Guided RFA for pNET Therapy.
| Author | Study Year | Number of Treated Patients | Number of Treated Lesions | Efficacy on Follow-Up Imaging *, n (%) | Adverse Events, (n) | |||
|---|---|---|---|---|---|---|---|---|
| Insulinoma | Non-Functional pNET | Incomplete Response | Partial Response | Complete Response | ||||
| Pai et al. [11] | 2015 | 2 | 0 | 2 | 0 (0) | 2 (100) ** | 0 (0) | None |
| Barthet et al. [66] | 2019 | 12 | 0 | 14 | 2 (14) | 0 (0) | 12 (86) | Acute pancreatitis with necrosis and bacteremia (1); MPD stenosis (1) |
| Oleinikov et al. [74] | 2019 | 18 | 9 | 18 | 1 (4) | 0 (0) | 26 (96) | Acute pancreatitis (2) |
| Marx et al. [75] | 2022 | 7 | 7 | 0 | 0 (0) | 0 (0) | 6 (100) | Mild abdominal pain (1); Acute pancreatitis (2); Coagulation necrosis of the superior mesenteric vein (1); Retro-gastric collection resulting in death (1) |
| Marx et al. [76] | 2022 | 27 | 0 | 27 | 0 (0) | 2 (7) | 25 (93) | Mild abdominal pain (3); Acute pancreatitis (4); Periprocedural bleeding (2); Pseudocyst formation (1); Pancreatic fistula formation (1); MPD stricture (1) |
| Figueiredo et al. [77] | 2022 | 29 *** | 13 | 10 | 2 (18) | 3 (27) | 6 (55) | Mild abdominal pain (4); Acute pancreatitis (3); MPD stenosis (1); Periprocedural bleeding (1); Gastric wall hematoma (1); Fever without infection (1) |
* Complete response is defined as the radiographic absence of residual lesion on post-procedural imaging. Incomplete response is defined as either persistent or enlarged residual lesion on post-procedural imaging. If the study authors noted reduction in lesion size without resolution on post-procedural imaging, this is considered a partial response; if this was not recorded by the study authors, these lesions are categorized as incomplete response. ** Although complete lesion resolution was not observed, cross-sectional imaging revealed changes in tumor vascularity in one patient and central necrosis of the tumor in the other. *** This number of treated patients reflects the inclusion of one case of PDAC and 11 metastatic lesions in 6 patients who were subjected to EUS-guided RFA as part of the study population. These patients are not included in the columns displaying tumor efficacy but are included in the adverse events column.